| Followers | 21 |
| Posts | 946 |
| Boards Moderated | 0 |
| Alias Born | 07/20/2020 |
Wednesday, August 24, 2022 5:33:11 AM
Thank you for this post. So if Pfizer has to do a trial for long haulers, then Revive will need to do one as well if they want to be considered as a solution for long haulers.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
